600196 复星医药
已收盘 01-16 15:00:00
资讯
新帖
简况
复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%
证券之星 · 01-14 22:09
复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%
复星医药子公司注射用乳糖酸红霉素注册申请获受理
北京商报 · 01-14 17:55
复星医药子公司注射用乳糖酸红霉素注册申请获受理
每周股票复盘：复星医药（600196）参投基金完成备案
证券之星 · 01-11
每周股票复盘：复星医药（600196）参投基金完成备案
复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理
美股速递 · 01-08
复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理
复星医药(600196.SH)控股子公司药品注册申请获受理
智通财经 · 01-08
复星医药(600196.SH)控股子公司药品注册申请获受理
复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%
证券之星 · 01-05
复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%
14亿元接盘“不良资产” 复星医药被质疑“豪赌”
经济参考报 · 01-05
14亿元接盘“不良资产” 复星医药被质疑“豪赌”
每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元
证券之星 · 01-02
每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元
上海复星医药2025年12月股份变动月报：A股期权与H股限制性股票单位计划实施中
中金财经 · 01-01
上海复星医药2025年12月股份变动月报：A股期权与H股限制性股票单位计划实施中
复星医药（600196）披露控股子公司药品临床试验进展，12月31日股价上涨0.11%
证券之星 · 2025-12-31
复星医药（600196）披露控股子公司药品临床试验进展，12月31日股价上涨0.11%
复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场
财中社 · 2025-12-30
复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场
每周股票复盘：复星医药（600196）拟控股投资绿谷医药
证券之星 · 2025-12-28
每周股票复盘：复星医药（600196）拟控股投资绿谷医药
复星医药：募投项目结项
南方财经网 · 2025-12-24
复星医药：募投项目结项
复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块
证券日报 · 2025-12-23
复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块
复星医药：控股子公司药品获美国FDA临床试验批准
南方财经网 · 2025-12-19
复星医药：控股子公司药品获美国FDA临床试验批准
官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”
市场资讯 · 2025-12-18
官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”
复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议
美股速递 · 2025-12-18
复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议
复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议
智通财经 · 2025-12-18
复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议
12月17日复星医药现784.3万元大宗交易
证券之星 · 2025-12-17
12月17日复星医药现784.3万元大宗交易
甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究
新京报 · 2025-12-16
甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.59,"timestamp":1768546801000,"preClose":27.82,"halted":0,"volume":17433559,"delay":0,"changeRate":-0.0083,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"已收盘","change":-0.23,"latestTime":"01-16 15:00:00","open":27.86,"high":28.14,"low":27.52,"amount":483000000,"amplitude":0.0223,"askPrice":27.59,"askSize":296,"bidPrice":27.58,"bidSize":283,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768786200000},"marketStatusCode":5,"adr":0,"adjPreClose":27.82,"symbolType":"stock","openAndCloseTimeList":[[1768527000000,1768534200000],[1768539600000,1768546800000]],"highLimit":30.6,"lowLimit":25.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.53,"roa":"--","peRate":22.443667,"roe":"5.3%","epsLYR":1.04,"committee":0.43271,"marketValue":73677000000,"turnoverRate":0.0082,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":21.08,"timestamp":1768550905004,"preClose":21.3,"halted":0,"volume":2822971,"delay":0,"premium":"-31.76"},"floatMarketCap":58449000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2603561455","title":"复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603561455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603561455?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:09","pubTimestamp":1768399757,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，复星医药报收于28.07元，较前一交易日下跌0.39%，最新总市值为749.59亿元。近日，复星医药发布关于控股子公司激励计划实施进展的公告。公告显示，其控股子公司复星安特金首期激励计划获修订，激励工具由期权变更为限制性股权，并设置分四期解锁条件，每期解锁比例上限为25%。2026年1月14日，复星安特金董事会确认存续有效的限制性股权为2,440,293份，对应注册资本244.0293万元，占总注册资本约2.9356%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400040959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0028","BK0096","BK0196","600196","02196","BK0060","BK1515","BK0175","BK0187","BK0188","BK0183","BK1191","BK0239","BK0012"],"gpt_icon":0},{"id":"2603469483","title":"复星医药子公司注射用乳糖酸红霉素注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603469483","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603469483?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:55","pubTimestamp":1768384537,"startTime":"0","endTime":"0","summary":"北京商报讯1月14日，复星医药发布公告称，公司控股子公司苏州二叶制药有限公司就注射用乳糖酸红霉素的药品注册申请于近期获国家药品监督管理局受理，拟用于治疗由特定微生物敏感株引起的感染、预防风湿热初发、预防风湿热复发以及预防细菌性心内膜炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143619068536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619068536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0188","BK1191","BK0060","BK1593","BK0096","02196","600196","BK0183","BK0028","BK0187","BK1515","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2602535834","title":"每周股票复盘：复星医药（600196）参投基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535834","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535834?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:14","pubTimestamp":1768068851,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，复星医药报收于27.65元，较上周的26.49元上涨4.38%。本周，复星医药1月9日盘中最高价报27.75元。本周关注点公司公告汇总：复星医药参与投资的华润（成都）医药产业股权投资基金已完成备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0096","BK0239","BK0060","BK0183","BK0175","BK0012","600196","BK1593","BK0187","02196","BK0028","BK1515","BK1191","BK0196"],"gpt_icon":0},{"id":"1188983081","title":"复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1188983081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188983081?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:25","pubTimestamp":1767867916,"startTime":"0","endTime":"0","summary":"复星医药近日宣布，其研发的富马酸福替尼胶囊新药注册申请已获得国家药品监督管理局正式受理。该进展标志着该创新药物向上市迈出关键一步，有望为相关疾病治疗提供新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0096","BK0196","600196","BK0060","BK0175","BK0187","BK0188","BK0183","BK0239","BK0012"],"gpt_icon":0},{"id":"2601357839","title":"复星医药(600196.SH)控股子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357839","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601357839?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:33","pubTimestamp":1767864812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司复星万邦(江苏)医药集团有限公司就丁二酸复瑞替尼胶囊(项目代号：SAF-189，申请注册分类：化药1类;简称“该新药”)再次递交的药品注册申请获国家药品监督管理局受理，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。该新药为创新型小分子化学药物。除本次申报适应症外，截至公告日期(即2026年1月8日)，该新药的另一适应症非小细胞肺癌(ROS1+)于中国境内(不包括中国港澳台地区)也已完成II期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0096","BK0239","BK0060","BK0183","BK0175","BK0012","600196","BK1593","BK0187","02196","BK0028","BK1515","BK1191","BK0196"],"gpt_icon":0},{"id":"2601300279","title":"复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601300279","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601300279?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:43","pubTimestamp":1767606194,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，复星医药报收于27.27元，较前一交易日上涨2.94%，最新总市值为728.23亿元。该股当日开盘26.58元，最高27.28元，最低26.58元，成交额达7.07亿元，换手率为1.24%。近日，复星医药发布关于参与设立之私募股权投资基金进展的公告。转让后，基金认缴规模仍为50,000万元，复星医药控股子公司大连复健、宁波复瀛合计认缴比例维持51%不变。大连引导基金成为新有限合伙人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0028","BK0096","BK0196","600196","02196","BK0060","BK1515","BK0175","BK0187","BK0188","BK0183","BK1191","BK0239","BK0012"],"gpt_icon":0},{"id":"2601024470","title":"14亿元接盘“不良资产” 复星医药被质疑“豪赌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601024470","media":"经济参考报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601024470?lang=zh_cn&edition=full","pubTime":"2026-01-05 04:50","pubTimestamp":1767559813,"startTime":"0","endTime":"0","summary":"2025年末，复星医药（600196.SH）抛出一项交易总额高达14.12亿元的收购方案，医药领域专业人士却直呼“看不懂”——一款原本在医药界都备受争议的产品，复星医药为何还要重金收购？由于标的公司品种因注册批件到期暂停销售，复星医药的收购也引来了上交所的监管问询。尽管复星医药随后进行回复并于12月30日举行对外投资事项说明会，但仍未打消市场疑虑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608050852.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608050852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK1593","BK0012","BK0028","BK0187","BK0239","BK0188","600196","BK0183","BK1515","BK0196","02196","BK0096","BK0175","BK1191"],"gpt_icon":0},{"id":"2600036920","title":"每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036920","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036920?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:59","pubTimestamp":1767293948,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周，复星医药12月22日盘中最高价报27.33元。该项目截至2025年11月累计研发投入约3,219万元。该药品尚需完成临床研究并经审批后方可上市，研发过程存在不确定性。股本股东变化截至2025年12月31日，复星医药普通股H股和A股的法定注册资本、已发行股份及库存股份数目均无变动。2025年A股期权计划项下88,700份期权失效，H股受限制股份单位计划下207,300份单位失效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"2600837930","title":"上海复星医药2025年12月股份变动月报：A股期权与H股限制性股票单位计划实施中","url":"https://stock-news.laohu8.com/highlight/detail?id=2600837930","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600837930?lang=zh_cn&edition=full","pubTime":"2026-01-01 11:23","pubTimestamp":1767237788,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月31日提交了截至当月的股份变动月报表。报告显示，公司法定/注册股本及已发行股份总数在本月内均未发生变化。其中，A股法定/注册股本为人民币2,118,488,825元，对应股份数量为2,118,488,825股；H股法定/注册股本为人民币551,940,500元，对应股份数量为551,940,500股。同时，根据公司2025年H股受限制股份单位计划，本月有207,300份受限制股份单位失效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260101/31909972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159982","BK0175","BK0188","BK1191","BK0060","BK1593","BK0096","02196","399300","600196","BK0183","BK0028","BK0187","BK1515","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2595259720","title":"复星医药（600196）披露控股子公司药品临床试验进展，12月31日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595259720","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595259720?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:44","pubTimestamp":1767174262,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，复星医药报收于26.49元，较前一交易日上涨0.11%，最新总市值为707.4亿元。该股当日开盘26.48元，最高26.58元，最低26.31元，成交额达2.75亿元，换手率为0.49%。公司近日发布公告称，其控股子公司成都星睿菁烜生物科技有限公司在中国境内启动诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。该药品尚需完成临床研究并经审批后方可上市，研发过程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1593","BK0175","02196","BK0188","BK1515","BK0183","BK0012","BK0239","BK1191","BK0028","BK0096","600196","BK0187","BK0060"],"gpt_icon":0},{"id":"2595795784","title":"复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2595795784","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595795784?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:03","pubTimestamp":1767088986,"startTime":"0","endTime":"0","summary":"12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605800274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4226","BK0183","BK0096","BK0187","02196","BK0175","BK1191","BK0028","BK0188","SRT","BK1515","BK0060","BK1593","BK0012","BK0196","BK0239","600196","BK4106"],"gpt_icon":0},{"id":"2594024193","title":"每周股票复盘：复星医药（600196）拟控股投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2594024193","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594024193?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:38","pubTimestamp":1766857092,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周关注点公司公告汇总：复星医药拟出资14.12亿元控股投资绿谷医药，标的公司主要产品甘露特钠胶囊已暂停生产和销售。公司公告汇总复星医药就控股投资绿谷医药事项回复上海证券交易所监管工作函。本次变动涉及吴中引导基金中心向吴中引导基金公司转让6,000万元基金份额，以及宁波复瀛向复星医药产业划转34,000万元基金份额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600196","BK0060","BK0175","09939","BK0183","BK0028","BK0239","BK0196","BK0012","BK1574","BK0096","BK1515","BK0187","159938","02196","BK1593","BK1161","BK1191"],"gpt_icon":0},{"id":"2593768604","title":"复星医药：募投项目结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2593768604","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593768604?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:05","pubTimestamp":1766570739,"startTime":"0","endTime":"0","summary":"南财智讯12月24日电，复星医药公告，截至2025年12月22日，公司2022年非公开发行募集资金已全部按承诺投入相关募投项目，专户中的募集资金（包括利息收入）已全部使用完毕，本次发行涉及的募投项目结项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600840925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0060","BK1191","BK0187","BK0096","BK0028","BK0012","BK0196","BK1515","BK1593","BK0239","BK0175","02196","600196","BK0183"],"gpt_icon":0},{"id":"2593413090","title":"复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413090","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413090?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:08","pubTimestamp":1766498900,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，复星医药在互动平台回答投资者提问时表示，公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块，其中药品、器械及诊断产品的主要市场包括中国、美国、欧洲及新兴市场在内的多个国家和地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599787764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK1583","BK0187","BK1191","BK4585","02196","159760","BK4581","159883","BK0012","BK1515","09996","BK1100","BK0196","BK1222","BK0183","09997","BK0096","BK0175","XBI","XLV","BK0188","BK0239","BK0060","BK0028","BK1593","BK4588","BK1574","01477","LABU"],"gpt_icon":0},{"id":"2592577131","title":"复星医药：控股子公司药品获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592577131","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592577131?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:20","pubTimestamp":1766136033,"startTime":"0","endTime":"0","summary":"南方财经12月19日电，复星医药(600196.SH)公告称，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司获美国FDA批准开展HLX18（重组抗PD-1人源化单克隆抗体注射液）用于治疗多种实体瘤的I期临床试验。复宏汉霖拟于条件具备后于美国开展该药品的I期临床试验。HLX18是复星医药自主研发的纳武利尤单抗生物类似药，拟用于多种癌症的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596838564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0239","BK0028","BK0187","BK0196","BK1515","BK1593","BK1191","BK0188","02196","BK0183","BK0175","BK0060","BK0096","600196"],"gpt_icon":0},{"id":"2592906229","title":"官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906229","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592906229?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:55","pubTimestamp":1766062500,"startTime":"0","endTime":"0","summary":" 多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批“吃螃蟹”的保险机构。一则“官宣！复星联合健康保险9款医疗险覆盖商保创新药！”复星联合健康保险的官宣无疑令业内欣喜。 复星联合健康保险“悔棋”动作的背后，与首次推出的《商业健康保险创新药品目录》不无关联。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfrcf8430514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0795875086.SGD","LU2360032135.SGD","LU1854104046.USD","LU0107464264.USD","LU2125154778.USD","SG9999017495.SGD","LU1066053197.SGD","SG9999014906.USD","600196","IE00BJJMRX11.SGD","LU2264538146.SGD","IE00B2B36J28.USD","LU0672654240.SGD","IE00BSNM7G36.USD","LU2271345857.HKD","LU1989771016.USD","LU0097036916.USD","LU2324357040.USD","LU0149725797.USD","LU0432979614.USD","LU2362541273.HKD","IE00B19Z9505.USD","LU0882574055.USD","LU2028103732.USD","BK4585","LU0943347566.SGD","LU1267930730.SGD","IE00BWXC8680.SGD","LU2023251221.USD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","LU1854103824.USD","LU1084165304.USD","LU0128525689.USD","IE00B19Z9Z06.USD","IE00BZ1G4Q59.USD","LU2089283258.USD","SG9999002232.USD","IE0002141913.USD","LU0052756011.USD","LU1037948541.HKD","LU0820561909.HKD","IE00BN29S564.USD","IE0004445239.USD","SGXZ31699556.SGD","LU1003077747.HKD","LU1720051017.SGD","LU0795875169.SGD","SG9999018857.SGD","LU0187121727.USD","LU2087625088.SGD","LU2125154935.USD","LU2244417387.USD","LU0053666078.USD","SG9999018865.SGD","IE0005OL40V9.USD","LU0965508806.USD","SG9999013999.USD","SG9999002224.SGD","LU1814569148.SGD","BK1161","LU0320765059.SGD","LU2362541513.USD","LU2112291526.USD","BK4581","LU2242649171.HKD","LU2491050154.USD","LU0354030511.USD","LU0965509010.AUD","LU1548497426.USD","IE00B1BXHZ80.USD","LU1069347547.HKD","LU0683600562.USD","IE00B4R5TH58.HKD","LU0689472784.USD","LU1153585028.USD","LU2552382058.USD","LU0211328371.USD","LU0661504455.SGD","SG9999001176.USD","IE00BFSS8Q28.SGD","LU1323610961.USD","LU2491049909.HKD","LU0545039389.USD","LU1551013342.USD","LU1674673428.USD","BK4534","LU0158827781.USD","LU0456855351.SGD","LU1670628061.USD","LU0203345920.USD","LU1934455194.USD","SG9999014880.SGD","LU0079474960.USD","LU0820561818.USD","BK4588","LU1267930227.SGD","LU2461242641.AUD","LU2361044865.SGD","02196","LU0114720955.EUR","LU0203347892.USD","LU1066051225.USD","LU0354030438.USD","LU0553294199.USD","LU1988902786.USD","IE00BJJMRY28.SGD","LU1037948897.HKD","LU1934455863.HKD","LU1551013425.SGD","LU1023059063.AUD","IE00BFSS7M15.SGD","LU0353189680.USD","LU0820562030.AUD","SG9999001176.SGD","SGXZ99366536.SGD","LU2468319806.SGD","LU0976567544.SGD","LU0238689110.USD","LU0251132253.USD","IE00B19Z3B42.SGD","LU0787776722.HKD","LU1074936037.SGD","IE00B19Z8X17.USD","IE00B4JS1V06.HKD","LU1732799900.SGD","IE00B7KXQ091.USD","IE00B894F039.SGD","LU1061106388.HKD","LU0861579265.USD","LU1914381329.SGD","LU1720051108.HKD","LU1057294990.SGD","LU0077335932.USD","LU0345770993.USD","LU0738911758.USD","LU0949170772.SGD","LU0496365809.HKD","LU0417517546.SGD","LU0310799852.SGD","LU1267930573.SGD","LU0912757837.SGD","LU0342679015.USD","LU0029864427.USD","LU0310800379.SGD","LU1718418525.SGD","LU2347655156.SGD","LU1983299246.USD","LU0965509283.SGD","LU1035773651.USD","IE0004445015.USD","LU2552382215.SGD","SGXZ51526630.SGD","LU1791710582.SGD","SGXZ57979304.SGD","LU0256863811.USD","LU0058720904.USD","LU2362540622.SGD","BK4566","LU0289739699.SGD","LU0310800965.SGD","LU0211326839.USD","IE00B775H168.HKD","LU1670627923.USD","LU0708995401.HKD","LU2089284900.SGD","LU1732800096.USD","LU2279689827.SGD","LU2211815571.USD","LU2491050071.SGD","LU1778281490.HKD","LU0048584097.USD","LU0345770308.USD","LU0128525929.USD","LU1066051498.USD","LU0353189763.USD","LU0094547139.USD","IE00B19Z3581.USD","LU0198837287.USD","LU2133065610.SGD","LU0266013472.USD","LU1496350502.SGD","SGXZ81514606.USD","LU1119994496.HKD","LU1291159041.SGD","LU0211326755.USD","LU1791710400.SGD","IE00B19Z8W00.USD","LU2357305700.SGD","IE000M9KFDE8.USD","LU1066051811.HKD","LU0211327993.USD","LU0823416689.USD","LU2111349929.HKD","LU2361044949.HKD","IE00B7SZLL34.SGD","LU2236285917.USD","BK4533","BK4532","IE00BZ9MQY76.HKD","LU2552382132.HKD","LU1267930490.SGD","LU2361045086.USD","SG9999014914.USD","LU0011850046.USD","LU1934455277.USD","LU0316494557.USD","BK4154","LU0109391861.USD","LU2089984988.USD","SG9999014898.SGD","IE00BJJMRZ35.SGD","BK1574","IE00B19Z9P08.USD","IE00B1XK9C88.USD","LU0528227936.USD","LU1064131342.USD","LU0158827948.USD","IE00BJT1NW94.SGD","IE00BKPKM429.USD","LU0708994859.HKD","LU1261432733.SGD","LU1674673691.USD","IE00BFXG1179.USD","LU0557290698.USD","LU0122379950.USD","LU0965509101.SGD","LU1506573853.SGD","LU0234572021.USD","IE0002270589.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"1124569521","title":"复星医药旗下公司与Clavis Bio签署共同开发及独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1124569521","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124569521?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:34","pubTimestamp":1766054051,"startTime":"0","endTime":"0","summary":"复星医药旗下公司与Clavis Bio签署了共同开发及独家许可选项的协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0060","BK0183","600196","BK0012","BK0175","BK0187","BK0188","BK0028","BK0239","BK0096"],"gpt_icon":0},{"id":"2592972970","title":"复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972970","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592972970?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:29","pubTimestamp":1766053787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点并推进针对获选靶点化合物的临床前开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK1191","BK0028","BK1593","02196","BK0175","BK0196","BK0012","BK0239","BK0187","BK0188","BK0096","BK1515","BK0183","600196"],"gpt_icon":0},{"id":"2592419995","title":"12月17日复星医药现784.3万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592419995?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:50","pubTimestamp":1765965010,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日复星医药发生大宗交易，交易数据如下：大宗交易成交价格25.3元，相对当日收盘价折价5.84%，成交31万股，成交金额784.3万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生2笔大宗交易，合计成交9100.0手，折价成交1笔。截至2025年12月17日收盘，复星医药报收于26.87元，上涨0.45%，换手率0.69%，成交量14.57万手，成交额3.89亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK1593","BK1191","BK0012","BK0060","BK0188","BK0239","BK0183","BK1515","BK0196","BK0028","600196","BK0187","BK0175","BK0096"],"gpt_icon":0},{"id":"2591988977","title":"甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2591988977","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591988977?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:52","pubTimestamp":1765878774,"startTime":"0","endTime":"0","summary":"12月15日，复星医药宣布，控股子公司复星医药产业与绿谷（上海）医药科技有限公司（“绿谷医药”）及其现有相关股东共同签订相关投资协议，拟出资约14.12亿元控股收购绿谷医药。本次收购完成后，绿谷医药将成为复星医药控股子公司，其核心药品甘露特钠胶囊也将纳入复星医药创新药品管线，主要用于治疗轻度至中度阿尔茨海默病（AD）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163593128594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593128594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0188","BK0196","BK0096","BK1574","BK0175","BK0012","02196","600196","09939","BK0060","BK0187","BK1515","BK0028","BK0183","BK1161","BK1191","159938","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768552026709,"stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.04},{"period":"3month","weight":-0.0313},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1765},{"period":"ytd","weight":0.0502}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":0.0752},{"period":"3month","weight":0.0711},{"period":"6month","weight":0.1636},{"period":"1year","weight":0.2744},{"period":"ytd","weight":0.0362}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}